JMP Securities Reaffirms “Market Outperform” Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)

JMP Securities reiterated their market outperform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a report issued on Tuesday,Benzinga reports. They currently have a $21.00 price target on the biotechnology company’s stock, down from their previous price target of $22.00.

A number of other equities analysts have also weighed in on ENTA. JPMorgan Chase & Co. decreased their price target on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a report on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. Finally, Evercore ISI upgraded Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $19.50.

Enanta Pharmaceuticals Stock Performance

ENTA opened at $8.60 on Tuesday. Enanta Pharmaceuticals has a 1 year low of $8.00 and a 1 year high of $17.80. The company’s 50 day simple moving average is $10.81 and its 200 day simple moving average is $12.25. The stock has a market capitalization of $182.23 million, a PE ratio of -1.57 and a beta of 0.56.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC grew its stake in shares of Enanta Pharmaceuticals by 3.5% in the first quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock valued at $36,579,000 after buying an additional 70,000 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Enanta Pharmaceuticals by 7.5% in the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock worth $33,664,000 after acquiring an additional 134,292 shares during the period. Krensavage Asset Management LLC grew its position in Enanta Pharmaceuticals by 19.7% in the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock valued at $15,520,000 after acquiring an additional 246,736 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Enanta Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock valued at $4,946,000 after purchasing an additional 14,575 shares during the period. Finally, State Street Corp lifted its position in shares of Enanta Pharmaceuticals by 6.4% during the third quarter. State Street Corp now owns 449,975 shares of the biotechnology company’s stock worth $4,662,000 after purchasing an additional 27,147 shares in the last quarter. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.